Trochanteric Hip Fractures (AO A2) SHS With or Without Trochanteric Stabilizing Plate - Rct Using RSA

September 26, 2020 updated by: Frede Frihagen, Oslo University Hospital

Trochanteric Hip Fractures (AO A2) Treated With Sliding Hip Screw With or Without Trochanteric Stabilizing Plate - a Randomized Controlled Trial Using Radiostereometry.

Trochanteric fractures represent about half of the hip fractures (with femoral neck fractures as the other half). Trochanteric hip fractures are almost always treated surgically with internal fixation of the fracture. However there is a debate ongoing for what is the appropriate implant to use. For stable fracture patterns the evidence seems to be in favor of the sliding hip screw, but for the unstable fractures it is more unclear whether to use a intramedullary nail or sliding hip screw with or without a lateral support plate (TSP). The role of the TSP in clinical use remains unclear and very little has been published about this, but it is believed to be an important contributor of stability to the sliding hip screw construct. We are planning a randomized controlled trial on trochanteric hip fractures to establish a method for implanting the tantalum markers, to observe the fracture healing process and to further investigate the role of the TSP.

Study Overview

Detailed Description

Trochanteric fractures represent about half of the hip fractures (with femoral neck fractures as the other half), and are almost always treated surgically with internal fixation of the fracture. However, there is an ongoing debate on what is the appropriate implant to use. For stable fracture patterns the evidence seems to be in favour of the sliding hip screw, whereas for the unstable fractures it is unclear whether an intramedullary nail or a sliding hip screw with or without a lateral support plate should be the implant of choice. A series of studies is now planned at Oslo University Hospital in collaboration with Diakonhjemmet Hospital in hope to further clarify this debate. The use of the lateral/trochanteric support plate (TSP) is widespread in some regions (e.g. Norway, Sweden and parts of Britain), but virtually never used other places. The role of the TSP remains unclear and very little has been published on it's use, even though it is believed to be an important contributor of stability to the sliding hip screw construct.

Trochanteric fractures are mainly caused by a direct trauma, i.e mainly a fall from own height in the elderly. The fractures are most often classified using the Müller AO classification or the Evans/Jensen, but several other classification systems also exist. The ideal classification system should be easily applicable, reliable, and aid in treatment decision making.

The treatment of trochanteric fractures comprise perioperative and operative modalities. The perioperative modalities consist among others of medical optimalization preoperatively, early rehabilitation and prevention of new fractures by treating osteoporosis and preventing new falls. The main scope of the current study will, however, be the operative modalities.

Surgery for trochanteric fractures is performed mainly with fracture reduction on a traction table and internal fixation, using either an intramedullary (IM) nail or a sliding hip screw (SHS), both available in various designs from different manufacturers. The latest Cochrane review did not conclude on which implant is the superior. However, among stable fractures there are less reoperations with the SHS, mainly due to peri-implant femoral fractures after operation with an IM nail that. The more unstable fractures, namely the reverse oblique and subtrochanteric fractures, may obtain better results using an intramedullary nail, probably due to less secondary dislocations with resulting varus deformity, shaft-medialization and shortening. The evidence for this is, however, weak and the role of the TSP remains unclear.

Radiostereometry (RSA) is the most precise and accurate method to measure motion in vivo between different segments in orthopaedic research. To do so, radio-opaque tantalum markers are implanted into the bone defining different segments. Stereoradiographs are performed over time to detect movement and monitor the healing (or non healing) process. This movement can be calculated both as translations and rotations. They are ideal to describe and compare the stability of fracture systems. RSA has been used successfully in earlier studies on fracture healing. Due to the high accuracy and precision, RSA yield reliable results with relatively small study-groups. We plan to use RSA to measure fracture dislocation and time to healing in our studies.

The study will be on the function of the trochanteric support plate and it´s ability to prevent secondary dislocation in AO 31 A2 fractures. We will utilize RSA for measurements during follow-up.

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Oslo, Norway, 0408
        • Orthopedic Center, Ulleval University Hospital
      • Oslo, Norway
        • Diakonhjemmet Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • AO 31-A2
  • able to walk independently, aids such as crutches or walker allowed
  • able to consent
  • fit for surgery with SHS with or without TSP

Exclusion Criteria:

  • not willing or able to attain follow up
  • previous fracture or surgery with retained metal work in the same hip
  • concomitant disease that will shorten life expectancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: SHS without TSP
Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
Active Comparator: SHS with TSP
Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
Other Names:
  • Lateral Stabilizing Plate, Lateral Support Shield

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fracture displacement during healing measured with radiostereometry
Time Frame: 52 weeks
Will be measured by RSA postoperatively, before discharge and after 4, 8, 12, 24 and 52 weeks. Total displacement from first reading to the reading showing maximum displacement is the main outcome.
52 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perioperative blood loss
Time Frame: 1 week
1 week
Time of surgery
Time Frame: 1 week
1 week
Eq5d
Time Frame: 52 weeks
Health Related Quality of Life (Hrqol).
52 weeks
Eq5d
Time Frame: 26 weeks
Hrqol.
26 weeks
Eq5d
Time Frame: 12 weeks
Hrqol.
12 weeks
Eq5d
Time Frame: 8 weeks
Hrqol.
8 weeks
Eq5d
Time Frame: 4 weeks
Hrqol.
4 weeks
Time to union as measured by RSA (cessation of motion) and radiographs
Time Frame: Will be examined at 4, 8, 12, 26 and 52 weeks
When RSA shows that no motion has happened between two time points the fracture will be regarded as healed at the former time point.
Will be examined at 4, 8, 12, 26 and 52 weeks
Time to union as measured by plain radiographs and clinical findings
Time Frame: Will be examined at 4, 8, 12, 26 and 52 weeks
Composite endpoint: Healing defined by obliteration of fracture line radiographically and pain free weight bearing (except lateral pain from hardware), when this occurs the fracture will be considered healed.
Will be examined at 4, 8, 12, 26 and 52 weeks
Harris Hip Score
Time Frame: 52 weeks
Will be examined at 4, 8, 12, 26 and 52 weeks
52 weeks
Harris Hip Score
Time Frame: 26 weeks
Will be examined at 4, 8, 12, 26 and 52 weeks
26 weeks
Harris Hip Score
Time Frame: 12 weeks
Will be examined at 4, 8, 12, 26 and 52 weeks
12 weeks
Harris Hip Score
Time Frame: 8 weeks
Will be examined at 4, 8, 12, 26 and 52 weeks
8 weeks
Harris Hip Score
Time Frame: 4 weeks
Will be examined at 4, 8, 12, 26 and 52 weeks
4 weeks
Postoperative pain (NRS) while in hospital
Time Frame: 1 week
Pain at mobilization (NRS) at discharge
1 week
Timed Up and Go (Tug) test
Time Frame: 4 weeks
4 weeks
Timed Up and Go (Tug) test
Time Frame: 8 weeks
8 weeks
Timed Up and Go (Tug) test
Time Frame: 12 weeks
12 weeks
Timed Up and Go (Tug) test
Time Frame: 26 weeks
26 weeks
Timed Up and Go (Tug) test
Time Frame: 52 weeks
52 weeks
Pain (NRS)
Time Frame: 4 weeks
Maximum hip pain during the last week
4 weeks
Pain (NRS)
Time Frame: 8 weeks
Maximum hip pain during the last week
8 weeks
Pain (NRS)
Time Frame: 12 weeks
Maximum hip pain during the last week
12 weeks
Pain (NRS)
Time Frame: 26 weeks
Maximum hip pain during the last week
26 weeks
Pain (NRS)
Time Frame: 52 weeks
Maximum hip pain during the last week
52 weeks
Satisfaction with operated hip (NRS)
Time Frame: 4 weeks
4 weeks
Satisfaction with operated hip (NRS)
Time Frame: 8 weeks
8 weeks
Satisfaction with operated hip (NRS)
Time Frame: 12 weeks
12 weeks
Satisfaction with operated hip (NRS)
Time Frame: 26 weeks
26 weeks
Satisfaction with operated hip (NRS)
Time Frame: 52 weeks
52 weeks
Motion during healing as measured by radiostereometry.
Time Frame: 52 weeks
Will be measured by RSA postoperatively, before discharge and after 4, 8, 12, 24 and 52 weeks. Pattern and time of secondary displacement will be compared between the treatment groups during the first year postoperatively.
52 weeks
Motion during healing as measured by plain radiographs.,
Time Frame: 52 weeks
The rate and degree of secondary displacement during the first year will be compared between the groups.
52 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reoperation for healing problems
Time Frame: 52 weeks
Any additional surgery addressing healing problems or hardware failure
52 weeks
Mortality
Time Frame: 52 weeks
Any reason
52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Frede Frihagen, PhD, Oslo University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2014

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

November 12, 2014

First Submitted That Met QC Criteria

November 16, 2014

First Posted (Estimate)

November 19, 2014

Study Record Updates

Last Update Posted (Actual)

September 29, 2020

Last Update Submitted That Met QC Criteria

September 26, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 2014/475/REK SO B

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hip Fractures

Clinical Trials on Sliding Hip Screw without Trochanteric Stabilization Plate

3
Subscribe